Navigation Links
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
Date:10/21/2009

CAMBRIDGE, Massachusetts, October 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease, by the end of the year. The Company also announces that a treatment protocol for REPLAGAL, filed at the request of FDA, has been approved, and that it will support emergency IND requests. The early access program is being put in place in view of the announced supply restriction of the only currently marketed treatment for Fabry disease in the United States.

"We are eager to have the opportunity to offer REPLAGAL to Fabry patients in the United States," commented Sylvie Gregoire, President of Shire Human Genetic Therapies. "There is an abundance of long-term experience with REPLAGAL in Fabry patients since the product has been commercially available outside of the United States since 2001."

The treatment protocol and emergency IND will allow physicians to treat Fabry patients with REPLAGAL in advance of potential commercial availability in the U.S. Shire will initially provide REPLAGAL free of charge to patients. The current supply of REPLAGAL is projected to be adequate to meet anticipated global demand.

Patients and physicians can contact Shire's OnePath SM for more information: +1-866-888-0660, or http://www.onepath.com.

About REPLAGAL(R) (agalsidase alfa)

REPLAGAL is a human form of enzyme alpha-galactosidase A (a-Gal A) manufactured in a human cell line by gene activation. REPLAGAL is approved in 45 countries worldwide. REPLAGAL is not currently approved for commercial sale in the U.S.'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... MC Medical, a subsidiary of Mitsubishi Corporation (MCM), ... OH medical device company, have formally agreed to ... visualization system in Japan . It is ... Japan in the latter half of 2015. ... product portfolio in endoscopic surgery market in Japan ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
(Date:8/22/2014)... 2014  Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Saxelby , its President and Chief Executive Officer, will ... and as a member of the Board of Directors, ... replaced on an interim basis by Michael T. ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2Landauer, Inc. Announces Executive Management Change 2
... 12, 2011 Aribex, Inc., the worldwide leader in ... Award from the internationally-known 2011 Edison Best New Product ... ceremony at the historic Capitale ballroom in New York ... recognized in the Science and Medical Handheld or Miniaturized ...
... Asante Solutions, Inc. (Asante), a medical device company focused ... mark for its Pearl Insulin Pump, the only insulin ... mark is a European proof of conformity that certifies ... Asante has begun discussions with potential distribution partners in ...
Cached Medicine Technology:NOMAD by Aribex Receives Edison Best New Product Award 2Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2
(Date:8/22/2014)... Medicine team has found that targeted automated alerts ... infections in hospital patients with urinary catheters. In ... simplified, the rate of improvement dramatically increased. , ... need urinary catheters in the first place and ... catheters that have not been removed within a ...
(Date:8/22/2014)... (HealthDay News) -- Many Americans know little about how Ebola ... an outbreak in the United States, a new survey shows. ... that there will be a major Ebola outbreak in the ... immediate family member will get sick with the deadly virus ... of Public Health poll. However, those opinions don,t match ...
(Date:8/22/2014)... 22, 2014 Millennium Treatment Group, ... Lantana, FL, recently launched a new website. Patients, ... information can now find Millennium Treatment Group at ... went live at the beginning of July. Everything ... can be found on the website. There’s an ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... that teaches readers how they can use natural methods ... for years has caught the attention of Shane Michaels, ... only a condition that affects the skin, it can ... suffer from it,” reports Michaels. “The intense itching and ...
(Date:8/22/2014)... protein 11 (BIM) deletion in advanced non-small cell ... free survival (PFS) in epidermal growth factor receptor ... Asian patients. Also, BIM deletion independently predicts overall ... BIM protein can activate the programmed cell death ... BIM deletion has been detected in 12.8% of ...
Breaking Medicine News(10 mins):Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... maltreatment is associated with reductions in quality of life even ... that finds thaton averagevictims lose at least two years of ... professor Phaedra Corso and her colleagues at the Centers for ... people to assess the deficits in quality of life that ...
... Legendary music producer,and entertainment icon Quincy ... catastrophic earthquake that struck China and the ... recorded several public services,announcements for the American ... the,media ( http://www.redcross.org/QuincyJonesPSA )., (Photo: ...
... molecules fabricated in the laboratory have been shown to ... diabetes in animal models. The results of these studies ... Rangos Sr. Research Center at Childrens Hospital of Pittsburgh ... research study at Childrens Hospital, the scientists injected the ...
... N.C., May 28 Best Practices, LLC launched,this ... help,companies build more effective communication practices in the ... leading,pharmaceutical companies and interviews with district managers and ... on internal communication -- Percentage of time ...
... Sullivan was a born engineer. As a youngster, she ... with Tinker Toys. , Today, Sullivan, an assistant professor ... Merck Faculty Fellow, is applying her knowledge and talents ... materials for delivering healing drugs and gene therapies to ...
... PBM Holdings, Inc., a global,supplier of infant ... affiliate company, PBM (Guangzhou) Nutritionals Co., Ltd., has,donated ... PBM is,partnering with the Shanghai Bureau of Civil ... the Red Cross Society of China, to distribute ...
Cached Medicine News:Health News:Study: Child maltreatment victims lose 2 years of quality of life 2Health News:Study: Child maltreatment victims lose 2 years of quality of life 3Health News:Quincy Jones Lends Time and Talent to Support Red Cross Relief Efforts In China and Myanmar 2Health News:New vaccine approach prevents/reverses diabetes in lab study at Children's Hospital of Pittsburgh 2Health News:New vaccine approach prevents/reverses diabetes in lab study at Children's Hospital of Pittsburgh 3Health News:Research Study Shows That Pharmaceutical Field Sales Reps' Productivity Inhibited by Unnecessary Internal Communication 2Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 2Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 3Health News:PBM Companies Partner with the Red Cross to Donate Infant Formula to China Earthquake Victims 2
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
This optimal design addresses low-cost, simple, non-invasive ankle distraction....
... BTA stat Test is an ... qualitative detection of bladder tumor ... with bladder cancer. This test ... aid in the management of ...
... TheraTears Liquid Gel is a thicker version ... or for those who need a longer-lasting ... Liquid Gel is so long-lasting, it is ... preserved gels, there never needs to be ...
Medicine Products: